Medical therapy for advanced pancreatic cancer: work in progress.
نویسندگان
چکیده
منابع مشابه
Pancreaticobiliary cancer: the future aspects of medical oncology.
Pancreatic cancer is one of the most common and most lethal cancers in the Western world with a median survival of approximately 3 months. Thus far, the results of anti-cancer treatment have been dismal, with a median survival of only 20 months in resectable pancreatic cancer, and 6 months in advanced disease. Although combined chemoradiation results in improved local control, it has only a mod...
متن کاملreatment for Pancreatic Cancer : Current Therapy and ontinued Progress
s T n the last decade, continued efforts in pancreas cancer esearch have led to the development of new, more ffective therapies. Additionally, progress in understandng the molecular processes underlying the developent and progression of this disease provides hope for he development of more effective treatment strategies. ecent clinical trials have provided reason for hope that ovel chemotherapy...
متن کاملIs there a role for second line therapy in advanced pancreatic cancer?
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX)...
متن کاملPancreatic neoplasm in 2011: an update.
Pancreatic cancer still is a significant, unresolved therapeutic challenge with nearly similar incidence and mortality rates. It is the most lethal type of digestive cancer with a 5-year survival rate of 5%. Adjuvant chemotherapy remains to be gemcitabine alone or combined with infusional 5-fluorouracil with radiation therapy. Nevertheless, only a few patients survive for at least 5 years after...
متن کاملTargeted therapies for pancreatic cancer.
INTRODUCTION Pancreatic cancer is a devastating malignancy and a leading cause of cancer mortality. Furthermore, early diagnosis represents a serious hurdle for clinicians, as symptoms are non-specific and usually manifest in advanced, treatment-resistant stages of the disease. SOURCES OF DATA Here, we review the rationale and progress of targeted therapies currently under investigation. AR...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JOP : Journal of the pancreas
دوره 12 1 شماره
صفحات -
تاریخ انتشار 2011